<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04622423</url>
  </required_header>
  <id_info>
    <org_study_id>LiMeT</org_study_id>
    <secondary_id>22737</secondary_id>
    <nct_id>NCT04622423</nct_id>
  </id_info>
  <brief_title>Advanced Therapies for Liver Metastases</brief_title>
  <acronym>LiMeT</acronym>
  <official_title>Advanced Immune Gene and Cell Therapies for Liver Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Università Vita-Salute San Raffaele</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver metastases (MTS) are the main cause of death for patients affected by colorectal&#xD;
      carcinoma (CRC) and pancreatic ductal adenocarcinoma (PDAC), thus representing the major&#xD;
      unmet clinical need for these malignancies.&#xD;
&#xD;
      Based on preliminary and published data, the investigators hypothesize that innovative&#xD;
      immune, gene and cell therapy approaches might overcome the tolerogenic liver&#xD;
      microenvironment and represent powerful therapeutic tools for liver MTS of PDAC and CRC.&#xD;
&#xD;
      The investigators have therefore planned an observational clinical study to enroll distinct&#xD;
      cohorts of patients (i.e., metastatic CRC, metastatic and non-metastatic PDAC) and finely&#xD;
      characterize, through integrated state-of-the-art -omics, the immune and non-immune&#xD;
      microenvironment of their primary tumor and/or liver metastases. Healthy volunteers will be&#xD;
      enrolled as negative controls.&#xD;
&#xD;
      The investigators aim at identifying: i) actionable tumor associated antigens (TAAs) and&#xD;
      local immune suppressive and regulatory pathways; ii) biological parameters for early&#xD;
      diagnosis of relapse; iii) the effect of therapies on the shaping of anti-tumor immune&#xD;
      responses.&#xD;
&#xD;
      Data collected will be instrumental for the generation of novel advanced therapy medicinal&#xD;
      products (ATMPs). Indeed, this protocol is part of a multi-partner translational program,&#xD;
      supported by the AIRC 5 per Mille 2019 grant, focused on the development, validation and&#xD;
      implementation for clinical testing of ATMPs to ameliorate the cure of CRC and PDAC and&#xD;
      possibly help the study of other solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and rationale - CRC and PDAC are the second and fourth most common cause of cancer&#xD;
      death, respectively. Patients affected by these cancers die of liver MTS. Conventional&#xD;
      therapies are active in either primary tumors but fail in metastatic disease. The&#xD;
      effectiveness of immunotherapy by immune checkpoint blockade and adoptive cell therapy with&#xD;
      tumor-specific T cells is only partial or temporary in MTS from solid tumors, because of&#xD;
      local immunosuppressive mechanisms. This is particularly relevant for hepatic MTS, in which a&#xD;
      natural tolerogenic milieu may further sustain immunosuppression induced by cancer cells and&#xD;
      infiltrating immune cells, such as tumor associated macrophages (TAMs), myeloid-derived&#xD;
      suppressor cells (MDSCs), neutrophils, and regulatory T or B cells.&#xD;
&#xD;
      In this regard, evidence suggests that progression of primary or metastatic CRC correlates&#xD;
      with poor immune infiltration and inflammation. Moreover, our published results in primary&#xD;
      PDAC support a correlation between tumor progression and a strong type 2&#xD;
      anti-inflammatory/immunosuppressive signature. Efficacy of chemotherapy is known to rely also&#xD;
      on reactivation and/or repolarization of tumor targeting immune responses. Pre-surgical&#xD;
      chemotherapy may induce beneficial effects and potentially targetable changes in the immune&#xD;
      profile of CRC or PDAC MTS.&#xD;
&#xD;
      The investigators hypothesize that a combination of i) direct cancer cell killing by&#xD;
      adoptively transferred tumor-specific T cells and ii) indirect control of tumor progression&#xD;
      via reprogramming of the tumor microenvironment would control hepatic MTS of CRC and PDAC.&#xD;
&#xD;
      Thus the investigators propose a thorough characterization of the metastatic milieu in these&#xD;
      two cancer types to rationally shape, on the basis of similarities and differences,&#xD;
      innovative ATMPs.&#xD;
&#xD;
      Objectives - The investigators want to study:&#xD;
&#xD;
        1. the tumor mutational burden and composition of the metastatic tumor microenvironment in&#xD;
           the liver;&#xD;
&#xD;
        2. the inhibitory pathways that constrain immunity in liver MTS;&#xD;
&#xD;
        3. the antigenic and clonal breadth of anti-tumor T cell responses;&#xD;
&#xD;
        4. the spatial-temporal variations of effector and regulatory immune cells upon therapy.&#xD;
&#xD;
        5. the characteristics of tumor cells and their microenvironment in liver MTS versus&#xD;
           primary tumor&#xD;
&#xD;
      Our primary objectives will be:&#xD;
&#xD;
        1. to identify immune suppressive/exhaustion pathways&#xD;
&#xD;
        2. to develop a library of tumor-specific TCR (N≥5/tumor type) and identify new CAR targets&#xD;
           (N≥1/tumor type) in CRC and PDAC MTS&#xD;
&#xD;
      Study Design - This clinical protocol aims at deeply characterizing MTS tumor cells and their&#xD;
      microenvironment, including possibly informative dynamic modifications from pro-tumor to&#xD;
      anti-tumor profiles that may follow chemotherapy, which is administered pre-surgery&#xD;
      (neo-adjuvant) to a substantial fraction of patients. PDAC and CRC MTS patients will be&#xD;
      therefore characterized by either cross-sectional or longitudinal investigations on&#xD;
      chemotherapy-naïve vs -treated patients.&#xD;
&#xD;
      In addition, the investigators aim at comparing hepatic MTS with primary tumor, in order to&#xD;
      highlight dynamic qualitative modifications in cancer cells, immune infiltrates and&#xD;
      not-immune microenvironment that could facilitate disease progression toward metastatic&#xD;
      spread. These modifications may offer a window of opportunity for the optimal application of&#xD;
      our ATMPs. To this purpose, primary non-metastatic PDAC patients undergoing surgical&#xD;
      resection will be enrolled in this study and followed-up for monitoring the development of&#xD;
      metachronous liver MTS, that will be characterized and compared to their matched/not matched,&#xD;
      previously collected, primary tumor samples. Also, in those CRC MTS patients undergoing&#xD;
      synchronous resection of primary CRC and hepatic MTS, comparative analyses will be carried&#xD;
      out on tumor from both sites, allowing intra- and inter-patient profiling of both tumor&#xD;
      niches.&#xD;
&#xD;
      The investigators expect to collect samples and clinical data from at least:&#xD;
&#xD;
        -  200 metastatic CRC patients (either synchronous or metachronous);&#xD;
&#xD;
        -  200 non-metastatic PDAC patients, among whom 20% are expected to relapse and develop&#xD;
           liver MTS within 1 year since primary tumor resection (possibly providing MTS&#xD;
           biospecimens);&#xD;
&#xD;
        -  75 synchronous PDAC MTS patients and about 20 metachronous PDAC MTS patients, the latter&#xD;
           originally enrolled as primary non-metastatic patients for the longitudinal study, for a&#xD;
           total of 95 metastatic PDAC patients;&#xD;
&#xD;
        -  30 healthy volunteers, as negative controls. Almost 505 different subjects will be&#xD;
           enrolled in the protocol.&#xD;
&#xD;
      Different biological samples (peripheral blood, primary and/or metastatic tumor tissue,&#xD;
      portal blood) will be collected, in the course of the standard diagnostic and therapeutic&#xD;
      care of those patients, and will be in part directly analyzed and in part biobanked for&#xD;
      further studies. In parallel, clinical data will be collected from patients since the time of&#xD;
      enrollment in the study for a follow-up period of 2 years.&#xD;
&#xD;
      The statistical analysis of collected data will be performed throughout the clinical study,&#xD;
      starting 6 months after the enrollment of the first patient until 6 months after the end of&#xD;
      patients' follow-up, for a total of 7 years. The study will last 7 years.&#xD;
&#xD;
      The research activities will be organized and integrated in 6 work packages (WPs):&#xD;
&#xD;
        1. Collection of the material from patients with CRC and PDAC MTS to the liver and with&#xD;
           primary non-metastatic resectable PDAC;&#xD;
&#xD;
        2. Definition of the tumor mutational burden, epigenetic and gene expression profile of the&#xD;
           CRC and PDAC metastatic liver at bulk and at single cell level;&#xD;
&#xD;
        3. Evaluation of the molecular and cellular composition of CRC and, if possible, PDAC liver&#xD;
           MTS by NICHE-seq;&#xD;
&#xD;
        4. Characterization of the immune landscapes of CRC and, if possible, PDAC liver MTS by&#xD;
           high dimensional flow cytometry;&#xD;
&#xD;
        5. Validation of the molecular results obtained in 2) and 4).&#xD;
&#xD;
        6. Definition of the antigenic landscape and TCR repertoire of CRC and PDAC liver MTS&#xD;
           Longitudinal PDAC primary tumor immune microenvironment characterization.&#xD;
&#xD;
      The results obtained by the above mentioned WPs will be crossed with clinical follow-up data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Definition of tumor mutational burden, epigenetic and gene expression profile of the CRC and PDAC metastatic liver at bulk and at single cell level</measure>
    <time_frame>30 months</time_frame>
    <description>CRC/PDAC MTS samples will be analyzed by:&#xD;
Whole exome DNA sequencing&#xD;
RNA-sequencing&#xD;
ATAC sequencing&#xD;
Single cell RNA sequencing on sorted myelomonocytic and T cells infiltrating CRC/PDAC MTS samples.&#xD;
Naive vs chemotherapy treated lesions as well as primary vs MTS lesions will be compared to evaluate chemotherapy-induced modifications and the molecular evolution in the distinct tumor sites, respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterization of the immune landscapes of CRC and, if possible, PDAC liver MTS by high dimensional flow cytometry</measure>
    <time_frame>30 months</time_frame>
    <description>Single cell suspension of CRC and PDAC MTS and paired autologous PBMCs and portal blood harvested before and after pre-operatory chemotherapy, will be analyzed by a series of parallel polychromatic high dimensional 28 color flow cytometry panels to study:&#xD;
Conventional MHC-restricted Tab cells, the main anti-tumor effectors;&#xD;
Innate-like T cells;&#xD;
B cells;&#xD;
Myelomonocytic populations involved in the stimulation or suppression of anti-tumor responses.&#xD;
Whenever available, matched primary vs MTS lesions will be compared to evaluate the immune landscapes in the distinct tumor sites.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Histological validation of the molecular results obtained in 1. and 2.</measure>
    <time_frame>30 months</time_frame>
    <description>Validation of relevant markers and molecular pathways in terms of anatomical distribution, performed by polychromatic IF (up to 6 colors) and IHC (up to 4 colors) on MTS CRC and PDAC biopsies, perilesional parenchyma and, whenever available, matched primary tumor samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Definition of the antigenic landscape and TCR repertoire of CRC and PDAC liver MTS</measure>
    <time_frame>30 months</time_frame>
    <description>Identification of tumor-reactive TCRs will be pursued through different and complementary strategies:&#xD;
The most relevant inhibitory checkpoint genes/pathways expressed by MTS-TILs will be used to enrich for tumor specificities by cell sorting harvested from CRC/PDAC MTS tumors, portal, hepatic and peripheral blood sample. After their activation, responding T cell cultures will be subject to bulk and single-cell TCR seq;&#xD;
In samples characterized by a low percentage of MTS-TILs, single cell immune profiling will be performed in order to simultaneously determine gene expression and correctly pair chain TCR sequences from individual T cells;&#xD;
The library of tumor-specific TCRs identified will be transiently expressed in reporter Jurkat cells to confirm their tumor antigen specificity;&#xD;
Identification and functional validation of transmembrane molecules enriched in cancer cells as possible targets for CAR design.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the molecular and cellular composition of CRC and, if possible, PDAC liver MTS by NICHE-seq</measure>
    <time_frame>30 months</time_frame>
    <description>Application of NICHE-seq to freshly isolated human tissues using photoactivatable (cages) fluorophores able to permeate within the cells, in particular comparing ≥5 chemoterapy treated vs ≥5 naive CRC MTS samples and ≥3 PDAC MTS samples in order elucide the high-order spatial organization of immune cell types in the NICHE-seq area and their molecular pathways, at the same time. NICHE-seq and conventional scRNA seq will proceed side-by-side to compare results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection of clinical follow-up data</measure>
    <time_frame>30 months</time_frame>
    <description>2-year overall (OS), disease free survival (DFS) and other follow-up parameters (patient's status, CEA levels, Ca 19-9 levels, adjuvant chemotherapy after surgery, date and site of recurrence, treatment at recurrence) will be collected and possibly correlated with the markers and pathways identified and validated in primary outcome measures.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">505</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma (PDAC)</condition>
  <condition>Colorectal Cancer (CRC)</condition>
  <condition>Liver Metastasis</condition>
  <arm_group>
    <arm_group_label>PDAC liver-MTS</arm_group_label>
    <description>Adult patients with clinical /radiological diagnosis/suspicious of PDAC metastatic to the liver, with subsequent cytological/histological confirmation (stage IV disease, AJCC) from liver resection/metastasectomy or core liver biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRC liver-MTS</arm_group_label>
    <description>Adult patients with histologically or cytologically confirmed diagnosis of CRC metastatic to the liver with indication to surgical resection (upfront or after neoadjuvant therapy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary not-MTS PDAC</arm_group_label>
    <description>Adult patients with clinical/radiological diagnosis of primary non-metastatic PDAC, candidates for surgical resection with radical intent of the primary tumor (upfront surgery or after neoadjuvant therapy). These patients will be monitored for early diagnosis of metachronous hepatic PDAC MTS by follow up testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>Negative control for the clinical study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational study</intervention_name>
    <description>Biobanking of biospecimens; clinical follow-up; biological analyses on biospecimens; collection of clinical, molecular, genetic and immunological data.</description>
    <arm_group_label>CRC liver-MTS</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>PDAC liver-MTS</arm_group_label>
    <arm_group_label>Primary not-MTS PDAC</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      i) Peripheral venous blood (from patients and healthy volunteers): additional volume&#xD;
      collected during the diagnostic routine/as part of surgical resection/during blood donation&#xD;
      drawings; ii) Tissue specimens from liver MTS (from metastatic CRC and PDAC patients): extra&#xD;
      material collected during fine-needle ago-biopsies or resected in therapeutic surgical&#xD;
      resections; iii) Tissue specimens from primary tumors (from non-metastatic PDAC patients and&#xD;
      synchronous CRC MTS patients): extra material resected in therapeutic surgical resections;&#xD;
      iv) Portal blood (from non-metastatic PDAC patients): directly collected from venous vessels&#xD;
      which will be subsequently cut and removed during standard surgical procedure, but that drain&#xD;
      directly into the portal vein.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        In this study, we will enroll CRC and PDAC patients with hepatic MTS, primary not&#xD;
        metastatic PDAC patients and healthy volunteers. We will include eligible patients, that&#xD;
        will decide to participate in this study upon signing of the predisposed informed consent&#xD;
        form and that will receive health care assistance/treatment for their disease at IRCCS San&#xD;
        Raffaele.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion and exclusion criteria - CRC patients&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          1. Patients with histologically or cytologically confirmed diagnosis of CRC metastatic to&#xD;
             the liver (stage IV disease, AJCC)&#xD;
&#xD;
          2. Patients with indication to surgical resection and/or chemotherapy treatment&#xD;
&#xD;
          3. Age ≥18&#xD;
&#xD;
          4. ECOG PS 0-1 at enrollment&#xD;
&#xD;
          5. Written informed consent&#xD;
&#xD;
          6. Patients will be treated in IRCCS San Raffaele&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Pregnancy or lactation&#xD;
&#xD;
          2. Inability to provide a written informed consent&#xD;
&#xD;
          3. Extraepatic disease with the exception of selected cases in which the coexistence of&#xD;
             extrahepatic disease does not constitute an exclusion criterion for hepatic resective&#xD;
             surgery (for example in patients with extraepatic lesions in remission or in any case&#xD;
             stabilized by chemotherapy)&#xD;
&#xD;
          4. Severe comorbidities (e.g. cardiac diseases, history of psychiatric disabilities, HIV,&#xD;
             autoimmune disorders)&#xD;
&#xD;
          5. Concurrent or previous other malignancy within 5 years of study entry, except cured&#xD;
             basal or squamous cell skin cancer, superficial bladder cancer, prostate&#xD;
             intraepithelial neoplasm, carcinoma in-situ of the cervix, or other noninvasive or&#xD;
             indolent malignancy&#xD;
&#xD;
          6. Other conditions (medical or psychiatric) that in the judgment of Investigators would&#xD;
             make the patient an inappropriate candidate for the study&#xD;
&#xD;
        Inclusion and exclusion criteria - PDAC patients&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          1. Patients with clinical/radiological diagnosis/suspicious of pancreatic adenocarcinoma&#xD;
             metastatic to the liver, with subsequent cytological/histological confirmation (stage&#xD;
             IV disease, AJCC)&#xD;
&#xD;
          2. Age ≥18&#xD;
&#xD;
          3. Karnofsky performance status ≥50&#xD;
&#xD;
          4. Metastatic pancreatic adenocarcinoma patients with histological specimens from whole&#xD;
             liver metastasis biopsy or core liver biopsy collected at IRCCS San Raffaele and&#xD;
             stored in the institutional biobank Centro Risorse Biologiche (CRB-OSR)&#xD;
&#xD;
          5. Written Informed consent&#xD;
&#xD;
          6. Patients with clinical/radiological diagnosis of not metastatic primary PDAC that will&#xD;
             undergo pancreatic resection at IRCCS San Raffaele&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Severe comorbidities (e.g., cardiac diseases, history of psychiatric disabilities)&#xD;
             representing an absolute contraindication for whole or core liver metastasis biopsy&#xD;
&#xD;
          2. Pregnancy or lactation&#xD;
&#xD;
          3. Metastatic pancreatic adenocarcinoma patients enrolled in other research trials&#xD;
             entailing the analysis of the liver metastasis histological sample&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chiara Bonini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vita-Salute San Raffaele University, IRCCS San Raffaele</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chiara Bonini, MD</last_name>
    <phone>0226434790</phone>
    <email>bonini.chiara@hsr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giulia Di Lullo, PhD</last_name>
    <phone>0226433823</phone>
    <email>dilullo.giulia@hsr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>26431</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luca Antonio Aldrighetti, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monica Casucci, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco De Cobelli, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paolo Dellabona, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudio Doglioni, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Massimo Falconi, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matteo Iannacone, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renato Ostuni, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorenzo Piemonti, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Pia Protti, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michele Reni, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanni Tonon, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Lambert AW, Pattabiraman DR, Weinberg RA. Emerging Biological Principles of Metastasis. Cell. 2017 Feb 9;168(4):670-691. doi: 10.1016/j.cell.2016.11.037. Review.</citation>
    <PMID>28187288</PMID>
  </reference>
  <reference>
    <citation>Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.</citation>
    <PMID>28596308</PMID>
  </reference>
  <reference>
    <citation>Kitamura T, Qian BZ, Pollard JW. Immune cell promotion of metastasis. Nat Rev Immunol. 2015 Feb;15(2):73-86. doi: 10.1038/nri3789. Review.</citation>
    <PMID>25614318</PMID>
  </reference>
  <reference>
    <citation>Zheng C, Zheng L, Yoo JK, Guo H, Zhang Y, Guo X, Kang B, Hu R, Huang JY, Zhang Q, Liu Z, Dong M, Hu X, Ouyang W, Peng J, Zhang Z. Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. Cell. 2017 Jun 15;169(7):1342-1356.e16. doi: 10.1016/j.cell.2017.05.035.</citation>
    <PMID>28622514</PMID>
  </reference>
  <reference>
    <citation>Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013 Jul 25;39(1):74-88. doi: 10.1016/j.immuni.2013.06.014. Review.</citation>
    <PMID>23890065</PMID>
  </reference>
  <reference>
    <citation>Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006 Sep 29;313(5795):1960-4.</citation>
    <PMID>17008531</PMID>
  </reference>
  <reference>
    <citation>Mlecnik B, Van den Eynde M, Bindea G, Church SE, Vasaturo A, Fredriksen T, Lafontaine L, Haicheur N, Marliot F, Debetancourt D, Pairet G, Jouret-Mourin A, Gigot JF, Hubert C, Danse E, Dragean C, Carrasco J, Humblet Y, Valge-Archer V, Berger A, Pagès F, Machiels JP, Galon J. Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival. J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx123. Erratum in: J Natl Cancer Inst. 2018 Apr 1;110(4):438.</citation>
    <PMID>28922789</PMID>
  </reference>
  <reference>
    <citation>De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med. 2011 Mar 14;208(3):469-78. doi: 10.1084/jem.20101876. Epub 2011 Feb 21.</citation>
    <PMID>21339327</PMID>
  </reference>
  <reference>
    <citation>Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell. 2015 Dec 14;28(6):690-714. doi: 10.1016/j.ccell.2015.10.012. Review.</citation>
    <PMID>26678337</PMID>
  </reference>
  <reference>
    <citation>Nordby T, Hugenschmidt H, Fagerland MW, Ikdahl T, Buanes T, Labori KJ. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival. Eur J Surg Oncol. 2013 Jun;39(6):559-66. doi: 10.1016/j.ejso.2013.02.020. Epub 2013 Mar 14.</citation>
    <PMID>23498362</PMID>
  </reference>
  <reference>
    <citation>Tzeng CW, Fleming JB, Lee JE, Wang X, Pisters PW, Vauthey JN, Varadhachary G, Wolff RA, Katz MH. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford). 2012 Jun;14(6):365-72. doi: 10.1111/j.1477-2574.2012.00445.x. Epub 2012 Feb 28.</citation>
    <PMID>22568412</PMID>
  </reference>
  <reference>
    <citation>Tjaden C, Michalski CW, Strobel O, Giese N, Hennche AK, Büchler MW, Hackert T. Clinical Impact of Structured Follow-up After Pancreatic Surgery. Pancreas. 2016 Jul;45(6):895-9. doi: 10.1097/MPA.0000000000000564.</citation>
    <PMID>26646267</PMID>
  </reference>
  <reference>
    <citation>McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, Swanton C; TRACERx Consortium. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017 Nov 30;171(6):1259-1271.e11. doi: 10.1016/j.cell.2017.10.001. Epub 2017 Oct 26.</citation>
    <PMID>29107330</PMID>
  </reference>
  <reference>
    <citation>Früh M, Peters S. Genomic Features of Response to Combination Immunotherapy in Lung Cancer. Cancer Cell. 2018 May 14;33(5):791-793. doi: 10.1016/j.ccell.2018.04.005.</citation>
    <PMID>29763618</PMID>
  </reference>
  <reference>
    <citation>Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, Sanvito F, Ponzoni M, Doglioni C, Cristofori P, Traversari C, Bordignon C, Ciceri F, Ostuni R, Bonini C, Casucci M, Bondanza A. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018 Jun;24(6):739-748. doi: 10.1038/s41591-018-0036-4. Epub 2018 May 28.</citation>
    <PMID>29808007</PMID>
  </reference>
  <reference>
    <citation>Escobar G, Barbarossa L, Barbiera G, Norelli M, Genua M, Ranghetti A, Plati T, Camisa B, Brombin C, Cittaro D, Annoni A, Bondanza A, Ostuni R, Gentner B, Naldini L. Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens. Nat Commun. 2018 Jul 24;9(1):2896. doi: 10.1038/s41467-018-05315-0.</citation>
    <PMID>30042420</PMID>
  </reference>
  <reference>
    <citation>Medaglia C, Giladi A, Stoler-Barak L, De Giovanni M, Salame TM, Biram A, David E, Li H, Iannacone M, Shulman Z, Amit I. Spatial reconstruction of immune niches by combining photoactivatable reporters and scRNA-seq. Science. 2017 Dec 22;358(6370):1622-1626. doi: 10.1126/science.aao4277. Epub 2017 Dec 7.</citation>
    <PMID>29217582</PMID>
  </reference>
  <reference>
    <citation>Lepore M, Mori L, De Libero G. The Conventional Nature of Non-MHC-Restricted T Cells. Front Immunol. 2018 Jun 14;9:1365. doi: 10.3389/fimmu.2018.01365. eCollection 2018. Review.</citation>
    <PMID>29963057</PMID>
  </reference>
  <reference>
    <citation>Cortesi F, Delfanti G, Grilli A, Calcinotto A, Gorini F, Pucci F, Lucianò R, Grioni M, Recchia A, Benigni F, Briganti A, Salonia A, De Palma M, Bicciato S, Doglioni C, Bellone M, Casorati G, Dellabona P. Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression. Cell Rep. 2018 Mar 13;22(11):3006-3020. doi: 10.1016/j.celrep.2018.02.058.</citation>
    <PMID>29539427</PMID>
  </reference>
  <reference>
    <citation>Noviello M, Manfredi F, Ruggiero E, Perini T, Oliveira G, Cortesi F, De Simone P, Toffalori C, Gambacorta V, Greco R, Peccatori J, Casucci M, Casorati G, Dellabona P, Onozawa M, Teshima T, Griffioen M, Halkes CJM, Falkenburg JHF, Stölzel F, Altmann H, Bornhäuser M, Waterhouse M, Zeiser R, Finke J, Cieri N, Bondanza A, Vago L, Ciceri F, Bonini C. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nat Commun. 2019 Mar 25;10(1):1065. doi: 10.1038/s41467-019-08871-1.</citation>
    <PMID>30911002</PMID>
  </reference>
  <reference>
    <citation>Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, Wunderlich JR, Somerville RP, Rosenberg SA. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015 Dec 11;350(6266):1387-90. doi: 10.1126/science.aad1253. Epub 2015 Oct 29.</citation>
    <PMID>26516200</PMID>
  </reference>
  <reference>
    <citation>Mennonna D, Maccalli C, Romano MC, Garavaglia C, Capocefalo F, Bordoni R, Severgnini M, De Bellis G, Sidney J, Sette A, Gori A, Longhi R, Braga M, Ghirardelli L, Baldari L, Orsenigo E, Albarello L, Zino E, Fleischhauer K, Mazzola G, Ferrero N, Amoroso A, Casorati G, Parmiani G, Dellabona P. T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes. Gut. 2017 Mar;66(3):454-463. doi: 10.1136/gutjnl-2015-309453. Epub 2015 Dec 17.</citation>
    <PMID>26681737</PMID>
  </reference>
  <reference>
    <citation>Ruggiero E, Nicolay JP, Fronza R, Arens A, Paruzynski A, Nowrouzi A, Ürenden G, Lulay C, Schneider S, Goerdt S, Glimm H, Krammer PH, Schmidt M, von Kalle C. High-resolution analysis of the human T-cell receptor repertoire. Nat Commun. 2015 Sep 1;6:8081. doi: 10.1038/ncomms9081.</citation>
    <PMID>26324409</PMID>
  </reference>
  <reference>
    <citation>Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015 Apr 3;348(6230):69-74. doi: 10.1126/science.aaa4971. Review.</citation>
    <PMID>25838375</PMID>
  </reference>
  <reference>
    <citation>Balachandran VP, Łuksza M, Zhao JN, Makarov V, Moral JA, Remark R, Herbst B, Askan G, Bhanot U, Senbabaoglu Y, Wells DK, Cary CIO, Grbovic-Huezo O, Attiyeh M, Medina B, Zhang J, Loo J, Saglimbeni J, Abu-Akeel M, Zappasodi R, Riaz N, Smoragiewicz M, Kelley ZL, Basturk O; Australian Pancreatic Cancer Genome Initiative; Garvan Institute of Medical Research; Prince of Wales Hospital; Royal North Shore Hospital; University of Glasgow; St Vincent's Hospital; QIMR Berghofer Medical Research Institute; University of Melbourne, Centre for Cancer Research; University of Queensland, Institute for Molecular Bioscience; Bankstown Hospital; Liverpool Hospital; Royal Prince Alfred Hospital, Chris O'Brien Lifehouse; Westmead Hospital; Fremantle Hospital; St John of God Healthcare; Royal Adelaide Hospital; Flinders Medical Centre; Envoi Pathology; Princess Alexandria Hospital; Austin Hospital; Johns Hopkins Medical Institutes; ARC-Net Centre for Applied Research on Cancer, Gönen M, Levine AJ, Allen PJ, Fearon DT, Merad M, Gnjatic S, Iacobuzio-Donahue CA, Wolchok JD, DeMatteo RP, Chan TA, Greenbaum BD, Merghoub T, Leach SD. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017 Nov 23;551(7681):512-516. doi: 10.1038/nature24462. Epub 2017 Nov 8.</citation>
    <PMID>29132146</PMID>
  </reference>
  <reference>
    <citation>Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015 May;12(5):453-7. doi: 10.1038/nmeth.3337. Epub 2015 Mar 30.</citation>
    <PMID>25822800</PMID>
  </reference>
  <reference>
    <citation>Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, Spagnoli G, Mazzi B, Bellone M, Dellabona P, Protti MP. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med. 1999 Mar 1;189(5):871-6.</citation>
    <PMID>10049951</PMID>
  </reference>
  <reference>
    <citation>Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014 May 9;344(6184):641-5. doi: 10.1126/science.1251102.</citation>
    <PMID>24812403</PMID>
  </reference>
  <reference>
    <citation>Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, Kriley IR, Rosenberg SA. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med. 2016 Dec 8;375(23):2255-2262.</citation>
    <PMID>27959684</PMID>
  </reference>
  <reference>
    <citation>Lim WA, June CH. The Principles of Engineering Immune Cells to Treat Cancer. Cell. 2017 Feb 9;168(4):724-740. doi: 10.1016/j.cell.2017.01.016. Review.</citation>
    <PMID>28187291</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Maria Chiara Bonini</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Pancreatic ductal adenocarcinoma</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>PDAC</keyword>
  <keyword>CRC</keyword>
  <keyword>Liver metastases</keyword>
  <keyword>Tumor microenvironment</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Immune therapy</keyword>
  <keyword>Cell therapy</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>Tumor infiltrating lymphocytes</keyword>
  <keyword>ATMP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT04622423/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

